KalVista Pharmaceuticals (STU:4XC1) Beginning Cash Position : €40.17 Mil (As of Jan. 2025)

View and export this data going back to 2016. Start your Free Trial

What is KalVista Pharmaceuticals Beginning Cash Position?

KalVista Pharmaceuticals's Beginning Cash Position for the quarter that ended in Jan. 2025 was €40.17 Mil.

KalVista Pharmaceuticals's quarterly Beginning Cash Position declined from Jul. 2024 (€29.31 Mil) to Oct. 2024 (€29.24 Mil) but then increased from Oct. 2024 (€29.24 Mil) to Jan. 2025 (€40.17 Mil).

KalVista Pharmaceuticals's annual Beginning Cash Position declined from Apr. 2022 (€46.85 Mil) to Apr. 2023 (€28.03 Mil) but then increased from Apr. 2023 (€28.03 Mil) to Apr. 2024 (€52.41 Mil).

KalVista Pharmaceuticals Beginning Cash Position Historical Data

The historical data trend for KalVista Pharmaceuticals's Beginning Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

KalVista Pharmaceuticals Beginning Cash Position Chart

KalVista Pharmaceuticals Annual Data

Trend

Apr15

Apr16

Apr17

Apr18

Apr19

Apr20

Apr21

Apr22

Apr23

Apr24

Beginning Cash Position

Get a 7-Day Free Trial

29.45

13.20

46.85

28.03

52.41

KalVista Pharmaceuticals Quarterly Data
	Apr20	Jul20	Oct20	Jan21	Apr21	Jul21	Oct21	Jan22	Apr22	Jul22	Oct22	Jan23	Apr23	Jul23	Oct23	Jan24	Apr24	Jul24	Oct24	Jan25
Beginning Cash Position	Get a 7-Day Free Trial															52.94	21.49	29.31	29.24	40.17

KalVista Pharmaceuticals Beginning Cash Position Calculation

Beginning Cash Position is the cash and equivalents balance at the beginning of the accounting period, as indicated on the Cash Flow statement.

KalVista Pharmaceuticals Beginning Cash Position Related Terms

Thank you for viewing the detailed overview of KalVista Pharmaceuticals's Beginning Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

KalVista Pharmaceuticals Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » KalVista Pharmaceuticals Inc (STU:4XC1) » Definitions » Beginning Cash Position

Comparable Companies

Traded in Other Exchanges

KALV:USA 4XC1:Germany

Address

55 Cambridge Parkway, Suite 901 East, Cambridge, MA, USA, 02142

Website

https://www.kalvista.com

KalVista Pharmaceuticals Inc is a pharmaceutical company, which focuses on the discovery, development, and commercialization of small molecule protease inhibitors for a range of diseases. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema and diabetic macular edema; and oral plasma kallikrein inhibitors. Geographically it operates throughout the region of the United States. The company is also conducting preclinical development on a novel, oral, Factor XIIa inhibitor program.

KalVista Pharmaceuticals Headlines

No Headlines